Represent

Lobbying
Lobbying by AbbVie, Inc.

Lobbying Relationship

Client

AbbVie, Inc.

More records

Lobbying firm

AbbVie, Inc.

More records

S.142, Preserve Access to Affordable Generics and Biosimilars Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property
H.R. 830, HELP Copays Act S.1375, HELP Copays Act H.R. 5379, Lower Costs, More Transparency Act S. 1339, Pharmacy Benefit Manager Reform Act Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Issues related to the 340B program
Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program and smoothing out-of-pocket costs for patients Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues
H.R. 2673, American Innovation and R&D Competitiveness Act of 2023 S. 866, American Innovation and Jobs Act Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program
Issues related to antitrust and mergers & acquisitions

Duration: February 25, 2013 to present

General Issues: Copyright/Patent/Trademark, Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Labor Issues/Antitrust/Workplace, Budget/Appropriations, Trade (Domestic & Foreign), Disaster Planning/Emergencies, Science/Technology

Spending: about $64,740,000 (But it's complicated. Here's why.)

Agencies lobbied since 2013: U.S. Senate, House of Representatives, Treasury - Dept of, White House Office, Health & Human Services - Dept of (HHS), Council of Economic Advisers (CEA), Natl Economic Council (NEC), Commerce - Dept of (DOC), U.S. Trade Representative (USTR), Vice President of the U.S., Patent & Trademark Office (PTO), Health Resources & Services Administration (HRSA), Centers For Medicare and Medicaid Services (CMS), Medicare Payment Advisory Commission (MedPAC), State - Dept of (DOS), Veterans Affairs - Dept of (VA), Natl Security Council (NSC), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)

Bills mentioned

S.CON.RES.3: A concurrent resolution setting forth the congressional budget for the...

Sponsor: Michael B. Enzi (R-Wyo.)

H.R.244: Consolidated Appropriations Act, 2017

Sponsor: Paul Cook (R-Calif.)

H.R.601: Continuing Appropriations Act, 2018 and Supplemental Appropriations for...

Sponsor: Nita M. Lowey (D-N.Y.)

H.R.2810: National Defense Authorization Act for Fiscal Year 2018

Sponsor: William M. Thornberry (R-Texas)

H.R.3219: Make America Secure Appropriations Act, 2018

Sponsor: Kay Granger (R-Texas)

H.R.3268: Agriculture, Rural Development, Food and Drug Administration, and...

Sponsor: Robert B. Aderholt (R-Ala.)

H.CON.RES.71: Establishing the congressional budget for the United States Government...

Sponsor: Diane Black (R-Tenn.)

S.124: Preserve Access to Affordable Generics Act

Sponsor: Amy Klobuchar (D-Minn.)

S.1390: STRONGER Patents Act of 2017

Sponsor: Christopher A. Coons (D-Del.)

S.1681: A bill to require persons who undertake Federally funded research and...

Sponsor: Bernard Sanders (ID-Vt.)

S.64: Safe and Affordable Drugs from Canada Act of 2017

Sponsor: John McCain (R-Ariz.)

S.92: Safe and Affordable Drugs from Canada Act of 2017

Sponsor: John McCain (R-Ariz.)

S.204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina...

Sponsor: Ron Johnson (R-Wis.)

S.469: Affordable and Safe Prescription Drug Importation Act

Sponsor: Bernard Sanders (ID-Vt.)

S.771: Improving Access To Affordable Prescription Drugs Act

Sponsor: Al Franken (D-Minn.)

H.R.749: Lower Drug Costs through Competition Act

Sponsor: Kurt Schrader (D-Ore.)

H.R.878: Right to Try Act of 2017

Sponsor: Andy Biggs (R-Ariz.)

H.R.1231: RACE for Children Act

Sponsor: Michael McCaul (R-Texas)

S.456: RACE for Children Act

Sponsor: Michael Bennet (D-Colo.)

H.R.1245: Affordable and Safe Prescription Drug Importation Act

Sponsor: Elijah E. Cummings (D-Md.)

H.R.1480: Safe and Affordable Drugs from Canada Act of 2017

Sponsor: Chellie Pingree (D-Maine)

H.R.1628: American Health Care Act of 2017

Sponsor: Diane Black (R-Tenn.)

H.R.1776: Improving Access To Affordable Prescription Drugs Act

Sponsor: Jan Schakowsky (D-Ill.)

H.R.2430: FDA Reauthorization Act of 2017

Sponsor: Greg Walden (R-Ore.)

S.934: FDA Reauthorization Act of 2017

Sponsor: Lamar Alexander (R-Tenn.)

S.41: Medicare Prescription Drug Price Negotiation Act of 2017

Sponsor: Amy Klobuchar (D-Minn.)

S.251: Protecting Medicare from Executive Action Act of 2017

Sponsor: Ron Wyden (D-Ore.)

S.260: Protecting Seniors' Access to Medicare Act of 2017

Sponsor: John Cornyn (R-Texas)

H.R.242: Medicare Prescription Drug Price Negotiation Act of 2017

Sponsor: Peter Welch (D-Vt.)

H.R.849: Protecting Seniors Access to Medicare Act

Sponsor: Phil Roe (R-Tenn.)

H.J.RES.51: Approving the discontinuation of the process for consideration and...

Sponsor: Phil Roe (R-Tenn.)

S.J.RES.16: A joint resolution approving the discontinuation of the process for...

Sponsor: Ron Wyden (D-Ore.)

H.R.3921: HEALTHY KIDS Act

Sponsor: Michael C. Burgess (R-Texas)

S.1827: KIDS Act of 2017

Sponsor: Orrin G. Hatch (R-Utah)

H.R.820: Childhood Cancer STAR Act

Sponsor: Michael McCaul (R-Texas)

H.R.2028: Further Continuing and Security Assistance Appropriations Act, 2017

Sponsor: Mike Simpson (R-Idaho)

S.1413: Higher Education Tax Benefit Compliance Improvement Act

Sponsor: Daniel Coats (R-Ind.)

S.632: STRONG Patents Act of 2015

Sponsor: Christopher A. Coons (D-Del.)

S.2733: Venue Equity and Non-Uniformity Elimination Act of 2016

Sponsor: Jeff Flake (R-Ariz.)

H.R.5573: PRICED Act

Sponsor: Jan Schakowsky (D-Ill.)

S.3094: PRICED Act

Sponsor: Sherrod Brown (D-Ohio)

S.3056: CREATES Act of 2016

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.6: 21st Century Cures Act

Sponsor: Fred Upton (R-Mich.)

H.R.34: 21st Century Cures Act

Sponsor: Suzanne Bonamici (D-Ore.)

S.2700: FDA and NIH Workforce Authorities Modernization Act

Sponsor: Lamar Alexander (R-Tenn.)

H.R.3381: Childhood Cancer STAR Act

Sponsor: Michael McCaul (R-Texas)

H.R.2228: Safe and Affordable Drugs from Canada Act of 2015

Sponsor: Chellie Pingree (D-Maine)

S.122: Safe and Affordable Drugs from Canada Act of 2015

Sponsor: John McCain (R-Ariz.)

H.R.639: Improving Regulatory Transparency for New Medical Therapies Act

Sponsor: Joe Pitts (R-Pa.)

S.481: Improving Regulatory Transparency for New Medical Therapies Act

Sponsor: Orrin G. Hatch (R-Utah)

H.R.2570: Strengthening Medicare Advantage through Innovation and Transparency for...

Sponsor: Diane Black (R-Tenn.)

S.1396: Value-Based Insurance Design Seniors Copayment Reduction Act of 2015

Sponsor: John Thune (R-S.D.)

H.R.3012: Right to Try Act of 2015

Sponsor: Matt Salmon (R-Ariz.)

S.2912: Trickett Wendler Right to Try Act of 2016

Sponsor: Ron Johnson (R-Wis.)

H.R.6043: Fair Accountability and Innovative Research Drug Pricing Act of 2016

Sponsor: Jan Schakowsky (D-Ill.)

S.3335: Fair Accountability and Innovative Research Drug Pricing Act of 2016

Sponsor: Tammy Baldwin (D-Wis.)

S.3239: RACE for Children Act

Sponsor: Michael Bennet (D-Colo.)

H.R.4207: Medicare Fair Drug Pricing Act of 2015

Sponsor: Jan Schakowsky (D-Ill.)

S.1993: 21st Century Conservation Service Corps Act of 2015

Sponsor: John McCain (R-Ariz.)

S.2023: Prescription Drug Affordability Act of 2015

Sponsor: Bernard Sanders (ID-Vt.)

H.R.6501: Prescription Drug and Medical Device Price Review Board Act of 2016

Sponsor: Rosa DeLauro (D-Conn.)

S.3455: Pharmaceutical Supply and Value Enhancement Act

Sponsor: Amy Klobuchar (D-Minn.)

H.R.3061: Medicare Prescription Drug Price Negotiation Act of 2015

Sponsor: Peter Welch (D-Vt.)

S.31: Medicare Prescription Drug Price Negotiation Act of 2015

Sponsor: Amy Klobuchar (D-Minn.)

H.R.2005: Medicare Drug Savings Act of 2015

Sponsor: Kathy Castor (D-Fla.)

S.1083: Medicare Drug Savings Act of 2015

Sponsor: Bill Nelson (D-Fla.)

H.R.5122: To prohibit further action on the proposed rule regarding testing of...

Sponsor: Larry Bucshon (R-Ind.)

H.R.5278: PROMESA

Sponsor: Sean Duffy (R-Wis.)

H.R.4974: Military Construction and Veterans Affairs and Related Agencies...

Sponsor: Charlie Dent (R-Pa.)

S.2806: Military Construction, Veterans Affairs, and Related Agencies...

Sponsor: Mark Steven Kirk (R-Ill.)

S.2804: Energy and Water Development and Related Agencies Appropriations Act, 2017

Sponsor: Lamar Alexander (R-Tenn.)

H.R.2029: Consolidated Appropriations Act, 2016

Sponsor: Charlie Dent (R-Pa.)

H.R.406: Combination Drug Development Incentive Act of 2015

Sponsor: Jason Chaffetz (R-Utah)

S.1767: Combination Product Regulatory Fairness Act of 2016

Sponsor: Johnny Isakson (R-Ga.)

H.R.1537: Advancing Hope Act of 2015

Sponsor: G. K. Butterfield (D-N.C.)

S.1878: Advancing Hope Act of 2016

Sponsor: Bob Casey (D-Pa.)

H.R.9: Innovation Act

Sponsor: Robert W. Goodlatte (R-Va.)

H.R.3709: Helping our Rural Veterans Receive Health Care Act

Sponsor: Bruce Poliquin (R-Maine)

H.R.971: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015

Sponsor: Gus Bilirakis (R-Fla.)

S.1421: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015

Sponsor: Orrin G. Hatch (R-Utah)

S.2615: Increasing Competition in Pharmaceuticals Act

Sponsor: Susan Collins (R-Maine)

H.R.1101: Viral Hepatitis Testing Act of 2015

Sponsor: Brett Guthrie (R-Ky.)

S.1287: Viral Hepatitis Testing Act of 2015

Sponsor: Mark Steven Kirk (R-Ill.)

H.R.471: Ensuring Patient Access and Effective Drug Enforcement Act of 2015

Sponsor: Tom Marino (R-Pa.)

S.483: Ensuring Patient Access and Effective Drug Enforcement Act of 2016

Sponsor: Orrin G. Hatch (R-Utah)

H.R.1725: National All Schedules Prescription Electronic Reporting Reauthorization...

Sponsor: Edward Whitfield (R-Ky.)

S.480: National All Schedules Prescription Electronic Reporting Reauthorization...

Sponsor: Jeanne Shaheen (D-N.H.)

H.R.3677: Opioid Abuse Prevention and Treatment Act of 2015

Sponsor: Bill Foster (D-Ill.)

S.524: Comprehensive Addiction and Recovery Act of 2016

Sponsor: Sheldon Whitehouse (D-R.I.)

H.R.1102: Police Accountability Act of 2015

Sponsor: Hank Johnson (D-Ga.)

S.117: Jerusalem Embassy and Recognition Act of 2015

Sponsor: Dean Heller (R-Nev.)

H.R.3261: Medicare Prescription Drug Savings and Choice Act of 2015

Sponsor: Jan Schakowsky (D-Ill.)

S.1884: Medicare Prescription Drug Savings and Choice Act of 2015

Sponsor: Richard J. Durbin (D-Ill.)

H.R.880: American Research and Competitiveness Act of 2015

Sponsor: Kevin Brady (R-Texas)

H.R.1430: Permanent CFC Look-Through Act of 2015

Sponsor: Charles Boustany Jr. (R-La.)

H.R.415: Stop Corporate Inversions Act of 2015

Sponsor: Sander M. Levin (D-Mich.)

S.198: Stop Corporate Inversions Act of 2015

Sponsor: Richard J. Durbin (D-Ill.)

S.1946: Tax Relief Extension Act of 2015

Sponsor: Orrin G. Hatch (R-Utah)

H.R.5325: Continuing Appropriations and Military Construction, Veterans Affairs,...

Sponsor: Tom Graves (R-Ga.)

H.R.6174: Closing Loopholes for Orphan Drugs Act

Sponsor: Peter Welch (D-Vt.)

H.R.2298: Medicare Patient Safety and Drug Abuse Prevention Act

Sponsor: Gus Bilirakis (R-Fla.)

H.R.2914: Build a Better VA Act

Sponsor: Julia Brownley (D-Calif.)

H.R.1190: Protecting Seniors' Access to Medicare Act of 2015

Sponsor: Phil Roe (R-Tenn.)

S.141: Protecting Seniors' Access to Medicare Act of 2015

Sponsor: John Cornyn (R-Texas)

H.R.2925: Santa Cruz Valley National Heritage Area Act

Sponsor: Raúl M. Grijalva (D-Ariz.)

H.R.160: Protect Medical Innovation Act of 2015

Sponsor: Erik Paulsen (R-Minn.)

H.R.1806: America COMPETES Reauthorization Act of 2015

Sponsor: Lamar Smith (R-Texas)

S.1913: Stopping Medication Abuse and Protecting Seniors Act of 2015

Sponsor: Patrick J. Toomey (R-Pa.)

S.2786: Rural Access to Hospice Act of 2016

Sponsor: Shelley Moore Capito (R-W.Va.)

S.2895: Extending Justice for Sex Crime Victims Act of 2016

Sponsor: Dianne Feinstein (D-Calif.)

H.R.1809: No Federal Contracts for Corporate Deserters Act of 2015

Sponsor: Rosa DeLauro (D-Conn.)

H.R.248: American Job Protection Act

Sponsor: Charles Boustany Jr. (R-La.)

H.R.4900: PROMESA

Sponsor: Sean Duffy (R-Wis.)

S.2328: PROMESA

Sponsor: Roger Wicker (R-Miss.)

H.R.3762: To provide for reconciliation pursuant to section 2002 of the concurrent...

Sponsor: Tom Price (R-Ga.)

H.R.1078: Food and Drug Administration Safety Over Sequestration Act of 2015

Sponsor: Leonard Lance (R-N.J.)

H.R.3116: Quarterly Financial Report Reauthorization Act

Sponsor: Ted Lieu (D-Calif.)

S.3004: Alaska Native Claims Settlement Improvement Act of 2016

Sponsor: Lisa Murkowski (R-Alaska)

S.1720: Harriet Tubman Currency Tribute Act of 2015

Sponsor: Jeanne Shaheen (D-N.H.)

S.214: Shareholder Protection Act of 2015

Sponsor: Robert Menendez (D-N.J.)

H.R.3742: Access to Marketplace Insurance Act

Sponsor: Kevin Cramer (R-N.D.)

S.2260: Long-Term SCORE Act

Sponsor: Mark Warner (D-Va.)

H.R.3547: Lawrence J. Hackett Jr. Vietnam Veterans Agent Orange Fairness Act

Sponsor: John Katko (R-N.Y.)

H.R.2031: Anti-Swatting Act of 2015

Sponsor: Eliot L. Engel (D-N.Y.)

H.R.1890: Bipartisan Congressional Trade Priorities and Accountability Act of 2015

Sponsor: Paul D. Ryan (R-Wis.)

S.995: Bipartisan Congressional Trade Priorities and Accountability Act of 2015

Sponsor: Orrin G. Hatch (R-Utah)

S.320: Medical Innovation Act of 2015

Sponsor: Elizabeth Warren (D-Mass.)

S.2538: ICE Agent Support Act of 2016

Sponsor: Ted Cruz (R-Texas)

H.R.909: Andrea Sloan CURE Act

Sponsor: Michael McCaul (R-Texas)

S.740: Geospatial Data Act of 2015

Sponsor: Orrin G. Hatch (R-Utah)

H.R.1588: Transnational Criminal Organization Illicit Spotter Prevention and...

Sponsor: Martha McSally (R-Ariz.)

H.R.4464: Federal Aviation Research and Development Reauthorization Act of 2016

Sponsor: Eddie Bernice Johnson (D-Texas)

S.1137: PATENT Act

Sponsor: Charles E. Grassley (R-Iowa)

H.R.3723: Viral Hepatitis Testing Act of 2013

Sponsor: Bill Cassidy (R-La.)

H.R.3204: Drug Quality and Security Act

Sponsor: Fred Upton (R-Mich.)

S.957: Drug Supply Chain Security Act

Sponsor: Michael Bennet (D-Colo.)

S.621: Safe Prescribing Act of 2013

Sponsor: Joe Manchin III (D-W.Va.)

H.R.1285: To amend the Controlled Substances Act to make any substance containing...

Sponsor: Vern Buchanan (R-Fla.)

H.R.2031: TEST Act

Sponsor: Edward J. Markey (D-Mass.)

S.1281: Veterans and Servicemembers Employment Rights and Housing Act of 2013

Sponsor: Richard Blumenthal (D-Conn.)

H.R.3547: Consolidated Appropriations Act, 2014

Sponsor: Lamar Smith (R-Texas)

H.R.2725: Food and Drug Administration Safety Over Sequestration Act of 2013

Sponsor: Leonard Lance (R-N.J.)

S.1413: FDA User Fee Protection Act

Sponsor: Mark Pryor (D-Ark.)

S.1720: Patent Transparency and Improvements Act of 2013

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.3309: Innovation Act

Sponsor: Robert W. Goodlatte (R-Va.)

S.214: Preserve Access to Affordable Generics Act

Sponsor: Amy Klobuchar (D-Minn.)

H.R.3709: Protecting Consumer Access to Generic Drugs Act of 2013

Sponsor: Bobby L. Rush (D-Ill.)

H.R.3116: MODDERN Cures Act of 2013

Sponsor: Leonard Lance (R-N.J.)

H.R.2985: Combination Drug Development Incentive Act of 2013

Sponsor: Jason Chaffetz (R-Utah)

S.117: Medicare Prescription Drug Price Negotiation Act of 2013

Sponsor: Amy Klobuchar (D-Minn.)

H.R.1102: Medicare Prescription Drug Price Negotiation Act of 2013

Sponsor: Peter Welch (D-Vt.)

S.740: Medicare Drug Savings Act of 2013

Sponsor: John D. Rockefeller IV (D-W.Va.)

H.R.1588: Medicare Drug Savings Act of 2013

Sponsor: Henry A. Waxman (D-Calif.)

H.R.2925: Strengthening Medicare Anti-Fraud Measures Act of 2013

Sponsor: Kevin Brady (R-Texas)

H.R.3474: Hire More Heroes Act of 2014

Sponsor: Rodney Davis (R-Ill.)

H.R.4438: American Research and Competitiveness Act of 2014

Sponsor: Kevin Brady (R-Texas)

H.R.4464: Permanent CFC Look-Through Act of 2014

Sponsor: Charles Boustany Jr. (R-La.)

S.2260: EXPIRE Act of 2014

Sponsor: Ron Wyden (D-Ore.)

S.2360: Stop Corporate Inversions Act of 2014

Sponsor: Carl Levin (D-Mich.)

H.R.4679: Stop Corporate Inversions Act of 2014

Sponsor: Sander M. Levin (D-Mich.)

H.R.4985: Stop Corporate Expatriation and Invest in America's Infrastructure Act...

Sponsor: Chris Van Hollen (D-Md.)

S.2786: Corporate Inverters Earnings Stripping Reform Act of 2014

Sponsor: Charles E. Schumer (D-N.Y.)

H.R.5549: Pay What You Owe Before You Go Act

Sponsor: Lloyd Doggett (D-Texas)

S.2895: Pay What You Owe Before You Go Act

Sponsor: Sherrod Brown (D-Ohio)

H.R.4: Jobs for America Act

Sponsor: Dave Camp (R-Mich.)

H.R.5278: No Federal Contracts for Corporate Deserters Act of 2014

Sponsor: Rosa DeLauro (D-Conn.)

S.2704: No Federal Contracts for Corporate Deserters Act of 2014

Sponsor: Carl Levin (D-Mich.)

H.R.5750: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014

Sponsor: Gus Bilirakis (R-Fla.)

S.2538: Viral Hepatitis Testing Act of 2014

Sponsor: Mark Steven Kirk (R-Ill.)

H.R.3985: Stop Obamacare's Risky Provisions Act

Sponsor: Lynn Westmoreland (R-Ga.)

H.R.1558: Small Business Health Relief Act of 2013

Sponsor: Chris Collins (R-N.Y.)

H.R.1483: Stop Outsourcing Banking Enforcement and Examination Act

Sponsor: Maxine Waters (D-Calif.)

H.CON.RES.25: Establishing the budget for the United States Government for fiscal year...

Sponsor: Paul D. Ryan (R-Wis.)

S.CON.RES.8: An original concurrent resolution setting forth the congressional budget...

Sponsor: Patty Murray (D-Wash.)

H.R.1249: Common Sense Nutrition Disclosure Act of 2013

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.1370: An Act to amend the Homeland Security Act of 2002 to require the...

Sponsor: Michael McCaul (R-Texas)

H.R.2998: Military Construction, Veterans Affairs, and Related Agencies...

Sponsor: Charlie Dent (R-Pa.)

S.1519: National Defense Authorization Act for Fiscal Year 2018

Sponsor: John McCain (R-Ariz.)

S.CON.RES.25: An original concurrent resolution setting forth the congressional budget...

Sponsor: Michael B. Enzi (R-Wyo.)

H.RES.553: Providing for consideration of the concurrent resolution (H. Con. Res....

Sponsor: Rob Woodall (R-Ga.)

H.R.4117: Competitive DRUGS Act of 2017

Sponsor: Lloyd Doggett (D-Texas)

S.297: Increasing Competition in Pharmaceuticals Act

Sponsor: Susan Collins (R-Maine)

S.1131: Fair Accountability and Innovative Research Drug Pricing Act of 2017

Sponsor: Tammy Baldwin (D-Wis.)

H.R.1703: Medical Product Communications Act of 2017

Sponsor: Morgan Griffith (R-Va.)

H.RES.403: Supporting the designation of March 2018 as Endometriosis Awareness Month.

Sponsor: David Scott (D-Ga.)

S.J.RES.17: A joint resolution approving the discontinuation of the process for...

Sponsor: John Cornyn (R-Texas)

H.R.3922: CHAMPIONING HEALTHY KIDS Act

Sponsor: Greg Walden (R-Ore.)

H.R.1: An Act to provide for reconciliation pursuant to titles II and V of the...

Sponsor: Kevin Brady (R-Texas)

H.R.1625: Consolidated Appropriations Act, 2018

Sponsor: Edward Royce (R-Calif.)

H.R.1892: Bipartisan Budget Act of 2018

Sponsor: John B. Larson (D-Conn.)

H.R.195: Making further continuing appropriations for the fiscal year ending...

Sponsor: Steve Russell (R-Okla.)

H.R.5340: STRONGER Patents Act of 2018

Sponsor: Steve Stivers (R-Ohio)

S.2312: HELP Act

Sponsor: Bill Cassidy (R-La.)

S.2453: Ensuring the Value of the 340B Program Act of 2018

Sponsor: Charles E. Grassley (R-Iowa)

H.R.4710: 340B PAUSE Act

Sponsor: Larry Bucshon (R-Ind.)

S.RES.451: A resolution recognizing the significance of endometriosis as an unmet...

Sponsor: Tammy Duckworth (D-Ill.)

S.3158: Departments of Labor, Health and Human Services, and Education, and...

Sponsor: Roy Blunt (R-Mo.)

S.974: Creating and Restoring Equal Access to Equivalent Samples Act of 2018

Sponsor: Patrick J. Leahy (D-Vt.)

S.2601: BIG Data for IP Act

Sponsor: Christopher A. Coons (D-Del.)

H.R.2212: CREATES Act of 2017

Sponsor: Tom Marino (R-Pa.)

H.R.5247: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina...

Sponsor: Brian Fitzpatrick (R-Pa.)

H.R.5353: Eliminating Opioid Related Infectious Diseases Act of 2018

Sponsor: Leonard Lance (R-N.J.)

H.R.5598: 340B Optimization Act

Sponsor: Buddy Carter (R-Ga.)

H.R.5687: SOUND Disposal and Packaging Act

Sponsor: Richard Hudson (R-N.C.)

H.R.6071: SERV Communities Act

Sponsor: Doris Matsui (D-Calif.)

H.R.6142: Reducing Drug Waste Act of 2018

Sponsor: Lloyd Doggett (D-Texas)

S.2589: Comprehensive Opioid Recovery Centers Act of 2018

Sponsor: Margaret Hassan (D-N.H.)

S.637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017

Sponsor: Ron Wyden (D-Ore.)

S.1348: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive...

Sponsor: Ron Wyden (D-Ore.)

H.R.6157: Department of Defense and Labor, Health and Human Services, and...

Sponsor: Kay Granger (R-Texas)

S.2554: Patient Right to Know Drug Prices Act

Sponsor: Susan Collins (R-Maine)

H.R.6642: To amend title XIX of the Social Security Act to sunset the limit on the...

Sponsor: Michael C. Burgess (R-Texas)

S.64: Preserve Access to Affordable Generics and Biosimilars Act

Sponsor: Amy Klobuchar (D-Minn.)

H.R.1344: Competitive DRUGS Act of 2019

Sponsor: Lloyd Doggett (D-Texas)

H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019

Sponsor: Bobby L. Rush (D-Ill.)

H.R.1503: Orange Book Transparency Act of 2020

Sponsor: Robin Kelly (D-Ill.)

H.R.1506: FAIR Generics Act

Sponsor: Nanette Barragán (D-Calif.)

H.R.1520: Further Extension of Continuing Appropriations Act, 2021

Sponsor: Anna G. Eshoo (D-Calif.)

S.659: Biologic Patent Transparency Act

Sponsor: Susan Collins (R-Maine)

H.R.965: CREATES Act of 2019

Sponsor: David Cicilline (D-R.I.)

H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the...

Sponsor: Michael C. Burgess (R-Texas)

H.R.1046: Medicare Negotiation and Competitive Licensing Act of 2019

Sponsor: Lloyd Doggett (D-Texas)

S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive...

Sponsor: Ron Wyden (D-Ore.)

S.475: RxCAP Act of 2019

Sponsor: Ron Wyden (D-Ore.)

S.476: Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019

Sponsor: Ron Wyden (D-Ore.)

H.R.1: For the People Act of 2019

Sponsor: John Sarbanes (D-Md.)

S.1224: Stop STALLING Act

Sponsor: Amy Klobuchar (D-Minn.)

S.1416: Affordable Prescriptions for Patients Act of 2019

Sponsor: John Cornyn (R-Texas)

H.R.2113: Prescription Drug STAR Act

Sponsor: Richard E. Neal (D-Mass.)

S.1895: Lower Health Care Costs Act

Sponsor: Lamar Alexander (R-Tenn.)

H.R.2740: Labor, Health and Human Services, Education, Defense, State, Foreign...

Sponsor: Rosa DeLauro (D-Conn.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

S.2543: Prescription Drug Pricing Reduction Act of 2019

Sponsor: Charles E. Grassley (R-Iowa)

H.R.3991: Affordable Prescriptions for Patients Through Improvements to Patent...

Sponsor: Hank Johnson (D-Ga.)

H.R.4398: Affordable Prescriptions for Patients Through Promoting Competition Act...

Sponsor: David Cicilline (D-R.I.)

H.R.5133: Affordable Prescriptions for Patients Through Promoting Competition Act...

Sponsor: David Cicilline (D-R.I.)

H.R.19: Lower Costs, More Cures Act of 2019

Sponsor: Greg Walden (R-Ore.)

S.2911: Seniors Prescription Drug Relief Act of 2019

Sponsor: Bill Cassidy (R-La.)

H.R.6201: Families First Coronavirus Response Act

Sponsor: Nita M. Lowey (D-N.Y.)

H.R.1425: Patient Protection and Affordable Care Enhancement Act

Sponsor: Angie Craig (D-Minn.)

H.R.6383: Uterine Fibroid Research and Education Act of 2020

Sponsor: Yvette D. Clarke (D-N.Y.)

H.R.7647: To provide for a COVID-19-related delay regarding annual limitation on...

Sponsor: A. Donald McEachin (D-Va.)

S.3129: Lower Costs, More Cures Act of 2019

Sponsor: Michael D. Crapo (R-Idaho)

H.R.133: Consolidated Appropriations Act, 2021

Sponsor: Henry Cuellar (D-Texas)

H.R.2007: Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021

Sponsor: Yvette D. Clarke (D-N.Y.)

H.R.1: For the People Act of 2021

Sponsor: John Sarbanes (D-Md.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

H.R.19: Lower Costs, More Cures Act of 2021

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.2164: Lower Costs, More Cures Act of 2021

Sponsor: Michael D. Crapo (R-Idaho)

H.R.2891: Preserve Access to Affordable Generics and Biosimilars Act

Sponsor: Jerrold Nadler (D-N.Y.)

H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act...

Sponsor: David Cicilline (D-R.I.)

H.R.2883: Stop Stalling Access to Affordable Medications

Sponsor: Hakeem Jeffries (D-N.Y.)

H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent...

Sponsor: Hank Johnson (D-Ga.)

H.R.5260: Reduced Costs and Continued Cures Act

Sponsor: Scott Peters (D-Calif.)

H.R.3684: Infrastructure Investment and Jobs Act

Sponsor: Peter A. DeFazio (D-Ore.)

H.R.5376: Inflation Reduction Act of 2022

Sponsor: John Yarmuth (D-Ky.)

H.R.5801: HELP Copays Act

Sponsor: A. Donald McEachin (D-Va.)

S.2891: Restoring the America Invents Act

Sponsor: Patrick J. Leahy (D-Vt.)

S.2774: Pride in Patent Ownership Act

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.2617: Consolidated Appropriations Act, 2023

Sponsor: Gerald E. Connolly (D-Va.)

S.142: Preserve Access to Affordable Generics and Biosimilars Act

Sponsor: Amy Klobuchar (D-Minn.)

H.R.830: Help Ensure Lower Patient Copays Act

Sponsor: Buddy Carter (R-Ga.)

H.R.1: Lower Energy Costs Act

Sponsor: Steve Scalise (R-La.)

S.1375: HELP Copays Act

Sponsor: Roger Marshall (R-Kan.)

H.R.2673: American Innovation and R&D Competitiveness Act of 2023

Sponsor: Ron Estes (R-Kansas)

H.R.5376: Share the Savings with Seniors Act

Sponsor: Mariannette Miller-Meeks (R-Iowa)

S.866: American Innovation and Jobs Act

Sponsor: Margaret Hassan (D-N.H.)

H.R.5379: HHS COVID–19 Origin Transparency Act of 2023

Sponsor: Chip Roy (R-Texas)

S.1339: Pharmacy Benefit Manager Reform Act

Sponsor: Bernard Sanders (ID-Vt.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist	Covered positions?
Michael Boyd	Legislative Assistant, Rep. Jim Kolbe
Catherine Dratz	U.S. Senate Finance Committee
John Ford	Sr.Counsel House Energy&Commerce Com 98-08
Daniel Bachner	General Counsel (1/14-11/15): Office of Sen Chris Coons/Sen. Judiciary Cmte-Oversight Subcmte; Counsel (1/13-12/13): Office of Sen Chris Coons/Sen Judiciary Cmte-Bankruptcy Subcmte; Deputy Counsel (1/12-12/12): Office of Sen Chris Coons
Hayden Rhudy Kennedy	Sen Orrin Hatch, 1/2011-9/2013 Senior Health Policy Advisor: Sen Mike Enzi, Senate HELP Cmt. 11/2007-1/2011 Research Asst, Prof Staff Member; Sen Issakson, 3/2005-11/2007; Staff Asst, Asst Sched; Health LC
Binta Beard	9/2009-9/2010: Legislative Assistant/AAAS Fellow for Rep. Edward J. Markey; 9/2010-4/2014: Legislative Assistant, Senator Richard J. Durbin
Dorcas Adekunle	Legislative Assistant (1/2015-9/2015), Senior Counsel (9/2015-5/2017) and Chief Counsel (5/2017-12/2018) for Representative Bonnie Watson Coleman; Legislative Director and Deputy Chief of Staff (1/2019-11/2020) for Representative Susan Wild
Rachel Derby	Legislative Correspondent (9/2007-9/2009) for Senator Mel Martinez; Deputy Scheduler/Special Projects Aide (9/2009-8/2010) for Senator George LeMieux
Adele Witenstein	n/a
Christopher Leibundguth	n/a
Heather Strawn	n/a
Stephen Scango	n/a
Courtney Piron	n/a
Andrew Kaplan	n/a
Steven Scango	n/a
Catherine Ferguson	n/a
Crystal Riley	n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

1st Quarter, 2024

Q1 Report

In Q1, AbbVie, Inc. had in-house lobbyists. The report was filed on April 22. Original Filing: 301573504.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2023

Q4 Report

In Q4, AbbVie, Inc. had in-house lobbyists. The report was filed on Jan. 22. Original Filing: 301539084.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2023

Q3 Report

In Q3, AbbVie, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2023. Original Filing: 301513884.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2023

Q2 Report

In Q2, AbbVie, Inc. had in-house lobbyists. The report was filed on July 20, 2023. Original Filing: 301489413.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2023

Q1 Report

In Q1, AbbVie, Inc. had in-house lobbyists. The report was filed on April 20, 2023. Original Filing: 301465660.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2022

Q4 Report

In Q4, AbbVie, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2023. Original Filing: 301442116.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2022

Q3 Report

In Q3, AbbVie, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2022. Original Filing: 301417737.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2022

Q2 Report

In Q2, AbbVie, Inc. had in-house lobbyists. The report was filed on July 20, 2022. Original Filing: 301393856.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2022

Q1 Report

In Q1, AbbVie, Inc. had in-house lobbyists. The report was filed on April 20, 2022. Original Filing: 301370065.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2021

Q4 Report

In Q4, AbbVie, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2022. Original Filing: 301336481.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2021

Q3 Report

In Q3, AbbVie, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2021. Original Filing: 301313040.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2021

Q2 Report

In Q2, AbbVie, Inc. had in-house lobbyists. The report was filed on July 20, 2021. Original Filing: 301289358.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2021

Q1 Report

In Q1, AbbVie, Inc. had in-house lobbyists. The report was filed on April 20, 2021. Original Filing: 301264231.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2020

Q4 Report

In Q4, AbbVie, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2021. Original Filing: 301240679.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements (CMS 2482-F) CMS Most Favored Nation (MFN) Model interim final rule (MFN Rule), implementing President Trump's proposal to align drug prices in the United States with those available in economically similar countries

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2020

Q3 Report

In Q3, AbbVie, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2020. Original Filing: 301221683.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13938, White House Executive Order on Increasing Drug Importation to Lower Prices for American Patients Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2020

Q2 Report

In Q2, AbbVie, Inc. had in-house lobbyists. The report was filed on July 20, 2020. Original Filing: 301199740.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2020

Q1 Report

In Q1, AbbVie, Inc. had in-house lobbyists. The report was filed on April 20, 2020. Original Filing: 301179196.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Medicare Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2019

Q4 Report

In Q4, AbbVie, Inc. had in-house lobbyists. The report was filed on Jan. 21, 2020. Original Filing: 301124318.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to Medicare Part D and prescription drug pricing H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2019

Q3 Report

In Q3, AbbVie, Inc. had in-house lobbyists. The report was filed on Oct. 21, 2019. Original Filing: 301077094.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

HR. 3, Lower Drug Costs Now Act of 2019 - provisions related to non-interference, International Pricing Index Model and Medicare part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues CMS-9926-F: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2020, Final rule

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2019

Q2 Report

In Q2, AbbVie, Inc. had in-house lobbyists. The report was filed on July 22, 2019. Original Filing: 301056545.xml

Lobbying Issues

H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures S. 1224, Stop STALLING Act - Provisions related to citizen petitions S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs - Provisions related to Medicaid rebates H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P Proposed Rule: OIG-0936-P Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2019

Q1 Report

In Q1, AbbVie, Inc. had in-house lobbyists. The report was filed on April 22, 2019. Original Filing: 301036820.xml

Lobbying Issues

S. 64, Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019 - Provisions related to patent settlements H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 475, RxCAP Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P Proposed Rule: OIG-0936-P Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2018

Q4 Report

In Q4, AbbVie, Inc. had in-house lobbyists. The report was filed on Jan. 22, 2019. Original Filing: 301016860.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 4117: Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 - Patent Settlements H.R. 5340: The Support Technology & Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act of 2018 - Provisions related to reforms of Patent Trial and Appeal Board (PTAB) proceedings and other patent system reforms S. 124: Preserve Access to Affordable Generics Act - Provisions related to patent settlements S. 1390: STRONGER Patents Act of 2017 - Provisions related to reforms of PTAB proceedings and other patent system reforms Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO S. 2554:Patient Right to Know Drug Prices Act - provisions related to notification of agreements to the FTC and DOJ

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 4710: 340B Protecting Access for the Underserved and Safety-net Entities Act or PAUSE Act - Provisions related to the 340B program H.R. 5598: 340B Optimization Act - Provisions related to transparency in the 340B program H.R. 6071: SERV Communities Act - Provisions related to transparency in the 340B program S. 1131: Fair Accountability and Innovative Research Drug Pricing Act of 2017 - Provisions related to drug pricing S. 2312: HELP Act - Provisions related to 340B program S. 2453: Ensuring the Value of the 340B Program Act of 2018 - Provisions to increase transparency in the 340B program Drug cost and pricing policy issues Transparency policy issues Drug importation and counterfeiting policy issues 340B drug discount program policy issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 6642, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers S. 1348: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2017 - Provisions related to increases in the wholesale acquisition costs of prescription drugs Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues Transparency policy issues Anti-Kickback Statute policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Final Rule; Calendar Year (CY) 2018 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System final rule with comment period (CMS-1678-FC) - Revisions to the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2018 Proposed Rule: Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program (CMS-4182-P) CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2018

Q3 Report

In Q3, AbbVie, Inc. had in-house lobbyists. The report was filed on Oct. 22, 2018. Original Filing: 300996848.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 4117: Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 - Patent Settlements H.R. 5340: The Support Technology & Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act of 2018 - Provisions related to reforms of Patent Trial and Appeal Board (PTAB) proceedings and other patent system reforms S. 124: Preserve Access to Affordable Generics Act - Provisions related to patent settlements S. 1390: STRONGER Patents Act of 2017 - Provisions related to reforms of PTAB proceedings and other patent system reforms Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Draft legislation related to notification of agreements to the FTC and DOJ

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers S. 1348: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2017 - Provisions related to increases in the wholesale acquisition costs of prescription drugs Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues Transparency policy issues Anti-Kickback Statute policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Final Rule; Calendar Year (CY) 2018 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System final rule with comment period (CMS-1678-FC) - Revisions to the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2018 Proposed Rule: Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program (CMS-4182-P)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2018

Q2 Report

In Q2, AbbVie, Inc. had in-house lobbyists. The report was filed on July 20, 2018. Original Filing: 300974643.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 4117: Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 - Patent Settlements H.R. 5340: The Support Technology & Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act of 2018 - Provisions related to reforms of Patent Trial and Appeal Board (PTAB) proceedings and other patent system reforms S. 124: Preserve Access to Affordable Generics Act - Provisions related to patent settlements S. 974 Amendment: Hatch-Waxman Integrity Act of 2018 - Provisions related to inter partes review process S. 1390: STRONGER Patents Act of 2017 - Provisions related to reforms of PTAB proceedings and other patent system reforms S. 2601: BIG Data for IP Act - Provisions related to fee-setting authority Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Draft legislation related to notification of agreements to the FTC and DOJ Bayh-Dole march-in rights policy issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 2212: CREATES Act of 2017 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 4710: 340B Protecting Access for the Underserved and Safety-net Entities Act or PAUSE Act - Provisions related to the 340B program H.R. 5247: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 - Provisions related to use of unapproved medical products by patients with a terminal illness H.R. 5353; Leonard Lance, Eliminating Opioid Infectious Diseases Act of 2018 H.R. 5598: 340B Optimization Act - Provisions related to transparency in the 340B program H.R. 5687: SOUND Disposal and Packaging Act - To require improved packaging and disposal methods with respect to certain drugs H.R. 6071: SERV Communities Act - Provisions related to transparency in the 340B program H.R. 6142: Reducing Drug Waste Act of 2018 - Action plan and report on vial size waste S. 204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness S. 974: CREATES Act of 2017 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 1131: Fair Accountability and Innovative Research Drug Pricing Act of 2017 - Provisions related to drug pri S. 2312: HELP Act - Provisions related to 340B progr S. 2453: Ensuring the Value of the 340B Program Act of 2018 - Provisions to increase transparency in the 340B prog S. 2589: Comprehensive Opioid Recovery Centers Act of 2018 - Provisions related to CDC infection surveillance and other funding Drug cost and pricing policy issues Transparency policy issues Drug importation and counterfeiting policy issues Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues Limited distribution systems in the pharmaceutical supply chain policy issues FDA modernization policy issues 340B drug discount program policy issues 21st Century Cures Act (Public Law 114-255) - Provisions related to biopharmaceutical discovery, development, delivery, and transparency Senate HELP Committee Innovation Agenda - Provisions related to biopharmaceutical discovery and development of FDA policy Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Cancer drug vial size policy issue Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49)

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 - Provisions related to transparency of prescription drug pricing and pharmacy benefit manag S. 1348: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2017 - Provisions related to increases in the wholesale acquisition costs of prescription drugs Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues Part B reform including MedPAC recommendations and other policy issues Drug cost and pricing policy issues Transparency policy issues Alternative payment models policy issues Value-based purchasing arrangements policy issues Anti-Kickback Statute policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Medicaid rebates and waiver policy issues Final Rule; Calendar Year (CY) 2018 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System final rule with comment period (CMS-1678-FC) - Revisions to the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2018 Proposed Rule: Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program (CMS-4182-P)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2018

Q1 Report

In Q1, AbbVie, Inc. had in-house lobbyists. The report was filed on April 20, 2018. Original Filing: 300957306.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 297: Increasing Competition in Pharmaceuticals Act S. 469: Affordable and Safe Prescription Drug Importation Act S. 771: Improving Access to Affordable Prescription Drugs Act H.R. 749: Lower Drug Costs Through Competition Act H.R. 1231: RACE for Children Act H.R. 1245: Affordable and Safe Prescription Drug Importation Act H.R. 1776: Improving Access to Affordable Prescription Drugs Act S. 2312: HELP Act - Provisions related to 340B program S. 2453: Ensuring the Value of the 340B Program Act of 2018 - Provisions to increase transparency in the 340B program H.R. 4710: 340B Preserving Patient Access for the Underserved and Safety-Net Entities Act or PAUSE Act - Provisions related to the 340B program 340B drug discount program policy issues H.R. 749: Lower Drug Costs Through Competition Act S. 469: Affordable and Safe Prescription Drug Importation Act H.Res. 403: Supporting the designation of March 2018 as Endometriosis Awareness Month S.Res.451: A resolution recognizing the significance of endometriosis as an unmet chronic disease for women and designating March 2018 as "Endometriosis Awareness Month"

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 41: Medicare Prescription Drug Price Negotiation Act of 2017 S. 251: Protecting Medicare from Executive Action Act of 2017 S. 260: Protecting Seniors' Access to Medicare Act of 2017 H.R. 242: Medicare Prescription Drug Price Negotiation Act of 2017 H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 H.J.Res. 51: Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act S.J.Res. 16: A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act S.J.Res. 17: A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act Part D policy issues including non-interference and rebates policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues H.R. 3921: HEALTHY KIDS Act - Funding for the Childrens Health Insurance Program S. 1827: KIDS Act of 2017 - Funding for the Childrens Health Insurance Program H.R. 3922: Championing Healthy Kids Act - CHIP and CHC reauthorization

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2017

Q4 Report

In Q4, AbbVie, Inc. had in-house lobbyists. The report was filed on Jan. 22, 2018. Original Filing: 300935182.xml

Lobbying Issues

H.R.1370: Continuing Resolution through January 19, 2018 H.R. 2810: National Defense Authorization Act for Fiscal Year 2018 H.J.Res 123: Continuing Resolution through December 22, 2017 H.R.2998: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2018 S. 1519: National Defense Authorization Act for Fiscal Year 2018 S.0000: Department of Defense (Chairmans Mark) - Making appropriations for the Department of Defense for the fiscal year ending September 30, 2018 S.0000: Department of Homeland Security (Chairmans Mark) - Making appropriations for the Department of Homeland Security for the fiscal year ending September 30, 2018, and for other purposes. H.R. 244: Consolidated Appropriations Act of 2017 S. Con. Res. 25: Senate Budget Resolution H. Res 553: House Budget Resolution

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 64: Safe and Affordable Drugs from Canada Act of 2017 S. 92: Safe and Affordable Drugs from Canada Act of 2017 S. 297: Increasing Competition in Pharmaceuticals Act S. 469: Affordable and Safe Prescription Drug Importation Act S. 771: Improving Access to Affordable Prescription Drugs Act S. 1131: Fair Accountability and Innovative Research Drug Pricing Act of 2017 H.R. 749: Lower Drug Costs Through Competition Act H.R. 1231: RACE for Children Act S. 456: RACE for Children Act H.R. 1245: Affordable and Safe Prescription Drug Importation Act H.R. 1480: Safe and Affordable Drugs from Canada Act of 2017 H.R. 1628: American Health Care Act of 2017 H.R. 1776: Improving Access to Affordable Prescription Drugs Act Prescription Drug User Fee Act (PDUFA) reauthorization Biologics User Fee Act (BsUFA) reauthorization 340B drug discount program policy issues Orphan Drug Act policy issues Biologics Price Competition and Innovation Act (BPCIA) implementation issues Patient assistance program policy issues H.R. 2430: FDA Reauthorization Act of 2017 - Provisions related to user fee programs PL 114-255: 21st Century Cures, implementation H.R. 749: Lower Drug Costs Through Competition Act H.R.2430/S.934: FDA Reauthorization Act of 2017 S. 469: Affordable and Safe Prescription Drug Importation Act S. 1827: KIDS Act of 2017 H.R. 1703: Medical Product Communications Act of 2017 H.Res. 403: Supporting the designation of March 2018 as Endometriosis Awareness Month

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 41: Medicare Prescription Drug Price Negotiation Act of 2017 S. 251: Protecting Medicare from Executive Action Act of 2017 S. 260: Protecting Seniors' Access to Medicare Act of 2017 H.R. 242: Medicare Prescription Drug Price Negotiation Act of 2017 H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 H.J.Res. 51: Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act S.J.Res. 16: A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act S.J.Res. 17: A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act Part D policy issues including non-interference and rebates policy issues Center for Medicare and Medicaid Innovation (CMMI) transparency and other policy issues payment methodologies H.R. 3921: HEALTHY KIDS Act - Funding for the Childrens Health Insurance Program S. 1827: KIDS Act of 2017 - Funding for the Childrens Health Insurance Program H.R. 3922: Championing Healthy Kids Act - CHIP and CHC reauthorization

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2017

Q3 Report

In Q3, AbbVie, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2017. Original Filing: 300915362.xml

Lobbying Issues

S.Con.Res 3: Budget Resolution - Provisions related to the biopharmaceutical industry including importation and non-interference H.R. 244: Consolidated Appropriations Act, 2017 Budget of the United States Government, Fiscal Year 2018 - A New Foundation for American Greatness Implementation of the Military Construction and Veterans Affairs and Related Agencies H.R. 601: Continuing Appropriations Act, 2018 and Supplemental Appropriations for Disaster Relief Requirements Act, 2017 H.R. 2810: National Defense Authorization Act for Fiscal Year 2018 H.R. 3219: Make America Secure Appropriations Act, 2018 H.R. 3268: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018 H.Con.Res. 71: FY18 Budget Resolution S.Con.Res. __: FY 18 Budget Resolution

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 64: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation S. 92: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation S. 204: Trickett Wendler Right to Try Act of 2017 S. 469: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 771: Improving Access to Affordable Prescription Drugs Act H.R. 749: Lower Drug Costs Through Competition Act - Provisions related to generic drug approvals and priority review vouchers H.R. 878: Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness H.R. 1231: RACE for Children Act - Provisions related to pediatric studies S. 456: RACE for Children Act - Provisions related to pediatric studies H.R. 1245: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 1480: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation H.R. 1628: American Health Care Act of 2017 H.R. 1776: Improving Access to Affordable Prescription Drugs Act Prescription Drug User Fee Act (PDUFA) reauthorization Biologics User Fee Act (BsUFA) reauthorization 340B drug discount program policy issues Orphan Drug Act policy issues Biologics Price Competition and Innovation Act (BPCIA) implementation issues Patient assistance program policy issues H.R. 2430: FDA Reauthorization Act of 2017 - Provisions related to user fee programs PL 114-255-21st Century Cures, implementation H.R. 749-Lower Drug Costs Through Competition Act Better Care Reconciliation Act of 2017 Graham-Cassidy Amendment H.R.2430/S.934: FDA Reauthorization Act of 2017

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 41: Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 242: Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal Part D policy issues including non-interference and rebates policy issues Drug cost and pricing policy issues Center for Medicare and Medicaid Innovation (CMMI) transparency and other policy issues H.R. 3921-Healthy Kids Act S. 1827- Kids Act of 2017

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2017

Q2 Report

In Q2, AbbVie, Inc. had in-house lobbyists. The report was filed on July 20, 2017. Original Filing: 300895562.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 64: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation S. 92: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation S. 204: Trickett Wendler Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness S. 456: RACE for Children Act - Provisions related to pediatric studies S. 469: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 771: Improving Access to Affordable Prescription Drugs Act - Provisions related to drug pricing H.R. 749: Lower Drug Costs Through Competition Act - Provisions related to generic drug approvals and priority review vouchers H.R. 820: Childhood Cancer STAR Act - Provisions related to expanded access and other policy issues H.R. 878: Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness H.R. 1231: RACE for Children Act - Provisions related to pediatric studies H.R. 1245: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 1480: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation H.R. 1628: American Health Care Act of 2017 - Provisions related to the biopharmaceutical industry including repeal of brand pharmaceutical manufacturer fee and individual and employer mandates, insurance affordability provisions, and Medicaid reforms H.R. 1776: Improving Access to Affordable Prescription Drugs Act - Provisions related to drug pricing Prescription Drug User Fee Act (PDUFA) reauthorization Biologics User Fee Act (BsUFA) reauthorization 340B drug discount program policy issues Orphan Drug Act policy issues Biologics Price Competition and Innovation Act (BPCIA) implementation issues Patient assistance program policy issues H.R. 2430: FDA Reauthorization Act of 2017 - Provisions related to user fee programs

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2017

Q1 Report

In Q1, AbbVie, Inc. had in-house lobbyists. The report was filed on April 20, 2017. Original Filing: 300875330.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 64: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation S. 92: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation S. 204: Trickett Wendler Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness S. 456: RACE for Children Act - Provisions related to pediatric studies S. 469: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 771: Improving Access to Affordable Prescription Drugs Act - Provisions related to drug pricing H.R. 749: Lower Drug Costs Through Competition Act - Provisions related to generic drug approvals and priority review vouchers H.R. 820: Childhood Cancer STAR Act - Provisions related to expanded access and other policy issues H.R. 878: Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness H.R. 1231: RACE for Children Act - Provisions related to pediatric studies H.R. 1245: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 1480: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation H.R. 1628: American Health Care Act of 2017 - Provisions related to the biopharmaceutical industry including repeal of brand pharmaceutical manufacturer fee and individual and employer mandates, insurance affordability provisions, and Medicaid reforms H.R. 1776: Improving Access to Affordable Prescription Drugs Act - Provisions related to drug pricing Prescription Drug User Fee Act (PDUFA) reauthorization Biologics User Fee Act (BsUFA) reauthorization 340B drug discount program policy issues Orphan Drug Act policy issues Biologics Price Competition and Innovation Act (BPCIA) implementation issues Patient assistance program policy issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2016

Q4 Report

In Q4, AbbVie, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2017. Original Filing: 300853076.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 6, H.R. 34 & Public Law 114-255, 21st Century Cures Act; S. 2700, FDA and NIH Workforce Authorities Modernization Act; H.R. 3381, Childhood Cancer STAR Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; Public Law 111-148, The Patient Protection and Affordable Care Act; Public Law 111-152, The Health Care and Education Reconciliation Act; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation/Reauthorization of The Prescription Drug User Fee Act (PDUFA); Implementation/Reauthorization of The Biosimilars User Fee Act (BsUFA); H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3012 & S. 2912, Trickett Wendler Right to Try Act of 2016; H.R. 6043 & S. 3335, Fair Accountability and Innovative Research Drug Pricing Act of 2016; S.3239, RACE for Children Act; Expanded Access (legislation not introduced) H.R. 4207, Medicare Fair Drug Pricing Act of 2015; Clinton's 1993 Health Security Act; S. 2023, Prescription Drug Affordability Act of 2015; H.R. 6501, Prescription Drug and Medical Device Price Review Board Act of 2016; S.3455, Pharmaceutical Supply and Value Enhancement Act; Repeal and Replace Proposals for Public Law 111-148, The Patient Protection and Affordable Care Act (no legislation introduced);

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2016

Q3 Report

In Q3, AbbVie, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2016. Original Filing: 300838511.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 6, 21st Century Cures Act; S. 2700, FDA and NIH Workforce Authorities Modernization Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation/Reauthorization of The Prescription Drug User Fee Act (PDUFA); Implementation/Reauthorization of The Biosimilars User Fee Act (BsUFA); H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016; H.R. 3012 & S. 2912, Trickett Wendler Right to Try Act of 2016; H.R. 6043 & S. 3335, Fair Accountability and Innovative Research Drug Pricing Act of 2016; H.R. 6174, Closing Loopholes for Orphan Drugs Act; S.3239, RACE for Children Act; Expanded Access (legislation not introduced); H.R. 4207, Medicare Fair Drug Pricing Act of 2015; Clinton's 1993 Health Security Act;

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2016

Q2 Report

In Q2, AbbVie, Inc. had in-house lobbyists. The report was filed on July 20, 2016. Original Filing: 300816071.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 6, 21st Century Cures Act; S. 2700, FDA and NIH Workforce Authorities Modernization Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation of The Prescription Drug User Fee Act (PDUFA); Implementation of The Biosimilars User Fee Act (BsUFA); H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016; H.R. 3012 & S. 2912, Trickett Wendler Right to Try Act of 2016; Expanded Access to (draft legislation);

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1430, Permanent CFC Look-Through Act; H.R. 415 & S. 198, Stop Corporate Inversions Act; S. 2786, Corporate Inverters Earnings Stripping Reform; S. 2895, Pay What You Owe Before You Go Act; H.R. 1809, No Federal Contracts for Corporate Deserters Act; H.R. 248, American Job Protection Act; S. 1946, Tax Relief Extention Act of 2015; Administrations Tax Reform and Budget Proposals; Senate and House Committee Tax Reform Proposals; H.R. 1, Tax Reform Act of 2014 (as introduced in the 113th Congress) H.R. 4900, H.R. 5278 & S. 2328, PROMESA; Puerto Rican Economy and Debt Relief Proposals (no bills introduced); Proposals to reform domestic and international tax structures (no bills introduced; Issues related to international tax reform including transitioning to a territorial tax system;

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Amendment

AbbVie, Inc. amended a lobbying report for in-house lobbying in Q12016 on Oct. 28, 2016 Original Filing: 300841047.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 6, 21st Century Cures Act S. 2700, FDA and NIH Workforce Authorities Modernization Act; H.R. 3381, Childhood Cancer STAR Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 471 & S. 483, Ensuring Patient Access and Effective Drug Enforcement of 2015; H.R. 1725 & S. 480, National All Schedules Prescription Electronic Reporting Reauthorization of 2015; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation of The Prescription Drug User Fee Act (PDUFA); Implementation of The Biosimilars User Fee Act (BsUFA); Public Law 113-54, Drug Quality & Security Act; H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016;

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Amendment

AbbVie, Inc. amended a lobbying report for in-house lobbying in Q12016 on July 20, 2016 Original Filing: 300819598.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Amendment

AbbVie, Inc. amended a lobbying report for in-house lobbying in Q12016 on July 20, 2016 Original Filing: 300816079.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Amendment

AbbVie, Inc. amended a lobbying report for in-house lobbying in Q12016 on April 20, 2016 Original Filing: 300799757.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Q1 Report

In Q1, AbbVie, Inc. had in-house lobbyists. The report was filed on April 20, 2016. Original Filing: 300798917.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2015

Q4 Report

In Q4, AbbVie, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2016. Original Filing: 300778180.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 880, American Research and Competitiveness Act of 2015; H.R. 1430, Permanent CFC Look-Through Act; S. 2260, Expiring Provisions Improvement, Reform, and Efficiency (EXPIRE) Act of 2014; H.R. 415 & S. 198, Stop Corporate Inversions Act; S. 2786, Corporate Inverters Earnings Stripping Reform; S. 2895, Pay What You Owe Before You Go Act; H.R. 1809, No Federal Contracts for Corporate Deserters Act; S. 1946, Tax Relief Extension Act of 2015; H.R. 1, Tax Reform Act of 2014; Innovation Promotion Act of 2015 (Not yet introduced); Administrations Tax Reform and 2016 Budget Proposals; Senate and House Committee Tax Reform Proposals; Proposals to reform domestic and international tax structures (no bills introduced); Senate Finance Committee Tax Reform Working Groups;

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Q3 Report

In Q3, AbbVie, Inc. had in-house lobbyists. The report was filed on Oct. 19, 2015. Original Filing: 300758436.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2015

Amendment

AbbVie, Inc. amended a lobbying report for in-house lobbying in Q22015 on Oct. 19, 2015 Original Filing: 300758113.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2015

Q2 Report

In Q2, AbbVie, Inc. had in-house lobbyists. The report was filed on July 20, 2015. Original Filing: 300744847.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2015

Amendment

AbbVie, Inc. amended a lobbying report for in-house lobbying in Q12015 on Oct. 19, 2015 Original Filing: 300758084.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2015

Q1 Report

In Q1, AbbVie, Inc. had in-house lobbyists. The report was filed on April 20, 2015. Original Filing: 300724903.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2014

Q4 Report

In Q4, AbbVie, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2015. Original Filing: 300705842.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 4438, American Research and Competitiveness Act of 2014; H.R. 4464, Permanent CFC Look-Through Act of 2014; S. 2260, Expiring Provisions Improvement, Reform, and Efficiency (EXPIRE) Act of 2014; Administrations Tax Reform and 2015 Budget Proposals; Senate and House Committee Tax Reform Proposals; Proposals to reform domestic and international tax structures (no bills introduced); S. 2360, Stop Corporate Inversions Act of 2014; HR 4679, Stop Corporate Inversions Act of 2014; HR 4985, Stop Corporate Expatriation and Invest in Americas Infrastructure Act of 2014; S. 2786, Corporate Inverters Earnings Stripping Reform Act of 2014; H.R. 5549 and S. 2895, Pay What You Owe Before You Go Act; H.R. 4, Jobs for America Act; H.R. 5278 and S. 2704, No Federal Contracts for Corporate Deserters Act;

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Amendment

AbbVie, Inc. amended a lobbying report for in-house lobbying in Q32014 on May 7, 2015 Original Filing: 300729456.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 3474, Hire More Heroes Act of 2014; H.R. 4438, American Research and Competitiveness Act of 2014; H.R. 4464, Permanent CFC Look-Through Act of 2014; S. 2260, Expiring Provisions Improvement, Reform, and Efficiency (EXPIRE) Act of 2014; Administrations Tax Reform and 2015 Budget Proposals; Senate and House Committee Tax Reform Proposals; Proposals to reform domestic and international tax structures (no bills introduced); S. 2360, Stop Corporate Inversions Act of 2014; HR 4679, Stop Corporate Inversions Act of 2014; HR 4985, Stop Corporate Expatriation and Invest in Americas Infrastructure Act of 2014; S. 2786, Corporate Inverters Earnings Stripping Reform Act of 2014; H.R. 5549 and S. 2895, Pay What You Owe Before You Go Act; H.R. 4, Jobs for America Act; H.R. 5278 and S. 2704, No Federal Contracts for Corporate Deserters Act;

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Q3 Report

In Q3, AbbVie, Inc. had in-house lobbyists. The report was filed on Oct. 17, 2014. Original Filing: 300680821.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2014

Q2 Report

In Q2, AbbVie Inc. had in-house lobbyists. The report was filed on July 21, 2014. Original Filing: 300667640.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2014

Q1 Report

In Q1, AbbVie Inc. had in-house lobbyists. The report was filed on April 21, 2014. Original Filing: 300645539.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2013

Q4 Report

In Q4, AbbVie Inc. had in-house lobbyists. The report was filed on Jan. 21, 2014. Original Filing: 300624425.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Amendment

AbbVie Inc. amended a lobbying report for in-house lobbying in Q32013 on Jan. 21, 2014 Original Filing: 300624400.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Q3 Report

In Q3, AbbVie Inc. had in-house lobbyists. The report was filed on Oct. 21, 2013. Original Filing: 300603921.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2013

Amendment

AbbVie Inc. amended a lobbying report for in-house lobbying in Q22013 on Oct. 21, 2013 Original Filing: 300603948.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2013

Q2 Report

In Q2, AbbVie Inc. had in-house lobbyists. The report was filed on July 22, 2013. Original Filing: 300582619.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2013

Q1 Report

In Q1, AbbVie Inc. had in-house lobbyists. The report was filed on April 22, 2013. Original Filing: 300559990.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2013

Registration

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Legislators

Bills

Statements

Lobbying

Travel

Lobbyists

Disclosures Filed